RESUMEN
No disponible
Asunto(s)
Humanos , Prostaglandinas Sintéticas/efectos adversos , Prostaglandinas Sintéticas/farmacología , Prostaglandinas Sintéticas/uso terapéutico , Hiperemia/diagnóstico , Hiperemia/prevención & control , Hiperemia/terapia , Dermatitis Perioral/prevención & control , Dermatitis Perioral/terapia , Bimatoprost/efectos adversos , Prostaglandinas/efectos adversos , Travoprost/efectos adversosRESUMEN
Topical corticosteroids are the primary treatment for psoriasis. A patient with psoriasis being treated with topical fluocinonide for lesions on the extremities developed an erythematous facial eruption consistent with perioral dermatitis. When topical agents are applied, they often end up in unintended areas. The potential for drug-induced perioral dermatitis should be considered in psoriasis patients treated with potent topical corticosteroids.
Asunto(s)
Antiinflamatorios/efectos adversos , Dermatitis Perioral/inducido químicamente , Fluocinonida/efectos adversos , Desinfección de las Manos , Psoriasis/tratamiento farmacológico , Administración Cutánea , Antiinflamatorios/administración & dosificación , Antiinflamatorios/uso terapéutico , Dermatitis Perioral/prevención & control , Femenino , Fluocinonida/administración & dosificación , Fluocinonida/uso terapéutico , Humanos , Persona de Mediana EdadRESUMEN
Perioral dermatitis is common in children and, if untreated, characterized by a chronic course lasting for months. Provocation factors known for adults, especially topical or inhaled corticosteroids, are relevant in children as well. We present eight children - all of them with dry skin - who developed perioral dermatitis after using sunscreens based on micropigments. This suggests that children with dry skin are at increased risk for perioral dermatitis. A history of sunscreen use should be specifically sought in children with perioral dermatitis.
Asunto(s)
Dermatitis Alérgica por Contacto/etiología , Dermatitis Alérgica por Contacto/prevención & control , Dermatitis Perioral/inducido químicamente , Dermatitis Perioral/prevención & control , Protectores Solares/efectos adversos , Niño , Preescolar , Femenino , Humanos , MasculinoAsunto(s)
Dermatitis Perioral/diagnóstico , Enfermedades de los Labios/diagnóstico , Antiinflamatorios/uso terapéutico , Niño , Dermatitis Perioral/etiología , Dermatitis Perioral/prevención & control , Desonida/uso terapéutico , Humanos , Enfermedades de los Labios/etiología , Enfermedades de los Labios/prevención & control , Masculino , Pomadas/uso terapéutico , Vaselina/uso terapéutico , Factores de RiesgoRESUMEN
In humans and animal models of herpes simplex virus infection, zosteriform skin lesions have been described which result from anterograde spread of the virus following invasion of the nervous system. Such routes of viral spread have not been fully examined following corneal infection, and the possible pathologic consequences of such spread are unknown. To investigate this, recombinant viruses expressing reporter genes were generated to quantify and correlate gene expression with replication in eyes, trigeminal ganglia, and periocular tissue. Reporter activity peaked in eyes 24 h postinfection and rapidly fell to background levels by 48 h despite the continued presence of viral titers. Reporter activity rose in the trigeminal ganglia at 60 h and peaked at 72 h, concomitant with the appearance and persistence of infectious virus. Virus was present in the periocular skin from 24 h despite the lack of significant reporter activity until 84 h postinfection. This detection of reporter activity was followed by the onset of periocular disease on day 4. Corneal infection with a thymidine kinase-deleted reporter virus displayed a similar profile of reporter activity and viral titer in the eyes, but little or no detectable activity was observed in trigeminal ganglia or periocular tissue. In addition, no periocular disease symptoms were observed. These findings demonstrate that viral infection of periocular tissue and subsequent disease development occurs by zosteriform spread from the cornea to the periocular tissue via the trigeminal ganglion rather than by direct spread from cornea to the periocular skin. Furthermore, clinical evidence is discussed suggesting that a similar mode of spreading and disease occurs in humans following primary ocular infection.
Asunto(s)
Enfermedades de la Córnea/virología , Dermatitis Perioral/virología , Infecciones Virales del Ojo/virología , Herpes Simple/virología , Herpesvirus Humano 1 , Adolescente , Animales , Chlorocebus aethiops , Enfermedades de la Córnea/complicaciones , Enfermedades de la Córnea/tratamiento farmacológico , Dermatitis Perioral/prevención & control , Modelos Animales de Enfermedad , Infecciones Virales del Ojo/complicaciones , Infecciones Virales del Ojo/tratamiento farmacológico , Femenino , Eliminación de Gen , Genes Reporteros , Genoma Viral , Herpesvirus Humano 1/enzimología , Herpesvirus Humano 1/genética , Herpesvirus Humano 1/patogenicidad , Humanos , Luciferasas/genética , Masculino , Ratones , Fosfotransferasas/genética , Timidina/metabolismo , Ganglio del Trigémino/virología , Células Vero , beta-Galactosidasa/genéticaRESUMEN
A double-blind, placebo-controlled, randomized trial was carried out with the aim of proving efficacy of standardized balm mint cream [active ingredient: 1% Lo-701--dried extract from Melissa officinalis L. leaves (70:1)] for the therapy of herpes simplex labialis. Sixty six patients with a history of recurrent herpes labialis (at least four episodes per year) in one center were treated topically; 34 of them with verum and 32 with placebo. The cream had to be smeared on the affected area four times daily over five days. A combined symptom score of the values for complaints, size of affected area and blisters at day 2 of therapy was formed as the primary target parameter. There was a significant difference in the values of the primary target parameter between both treatment groups: verum 4.03 +/- 0.33 (3.0); placebo 4.94 +/- 0.40 (5.0); values given are mean +/- SEM (median) of the symptoms score on day 2 of therapy. The tested formulation is effective for the treatment of herpes simplex labialis. The significant difference in the combined symptom score on the second day of treatment is of particular importance having in mind that the complaints in patients suffering from herpes labialis are usually most intensive at that time. In addition to the shortening of the healing period, the prevention of a spreading of the infection and the rapid effect on typical symptoms of herpes like itching, tingling, burning, stabbing, swelling, tautness and erythema, the balm mint cream has a further advantage. The different mechanism of action of the balm mint extract rules out the development of resistance of the herpes virus. Some indication exists that the intervals between the periods with herpes might be prolonged with balm mint cream treatment.